Yvonne Bombard

PhD, BSc

Scientist, Li Ka Shing Knowledge Institute


Dr. Bombard is a genomics health services researcher and Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Assistant Professor at the University of Toronto in the Institute of Health Policy Management and Evaluation.  Her research focuses on evaluating the adoption of new genomic technologies in clinical practice. She also conducts public and patient engagement research to advance health technology assessment and health service delivery. Dr. Bombard is active in numerous international policy advisory committees; her research informs policy development in this area.  In 2014, Dr. Bombard was the inaugural recipient of the Maurice McGregor Award for Demonstrated Excellence and Leadership Potential from the Canadian Agency for Drugs and Technologies in Health (CADTH) and also received a ‘Rising Star’ award from CIHR’s Institute of Health Services and Policy Research in 2011. Recently, she has been awarded a CIHR Foundation grant as an Early Career Investigator, and she holds a CIHR New Investigator Award.

Dr. Bombard holds a Fellowship from Yale University (Health Policy), a Fellowship from the Memorial Sloan-Kettering Cancer Center (Cancer Genomics) and a Fellowship from the University of Toronto (Health Services Research).

Recent Publications

  1. Reuter, MS, Walker, S, Thiruvahindrapuram, B, Whitney, J, Cohn, I, Sondheimer, N et al.. The Personal Genome Project Canada: findings from whole genome sequences of the inaugural 56 participants. CMAJ. 2018;190 (5):E126-E136. doi: 10.1503/cmaj.171151. PubMed PMID:29431110 PubMed Central PMC5798982.
  2. Barg, CJ, Miller, FA, Hayeems, RZ, Bombard, Y, Cressman, C, Painter-Main, M et al.. What's Involved with Wanting to Be Involved? Comparing Expectations for Public Engagement in Health Policy across Research and Care Contexts. Healthc Policy. 2017;13 (2):40-56. . PubMed PMID:29274226 PubMed Central PMC5749523.
  3. Ormond, KE, Mortlock, DP, Scholes, DT, Bombard, Y, Brody, LC, Faucett, WA et al.. Human Germline Genome Editing. Am. J. Hum. Genet. 2017;101 (2):167-176. doi: 10.1016/j.ajhg.2017.06.012. PubMed PMID:28777929 PubMed Central PMC5544380.
  4. Scott, AM, Hofmann, B, Gutiérrez-Ibarluzea, I, Bakke Lysdahl, K, Sandman, L, Bombard, Y et al.. Q-SEA - a tool for quality assessment of ethics analyses conducted as part of health technology assessments. GMS Health Technol Assess. 2017;13 :Doc02. doi: 10.3205/hta000128. PubMed PMID:28326147 PubMed Central PMC5352988.
  5. Hayeems, RZ, Miller, FA, Barg, CJ, Bombard, Y, Carroll, JC, Tam, K et al.. Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis. J. Pediatr. 2017;184 :165-171.e1. doi: 10.1016/j.jpeds.2017.01.049. PubMed PMID:28279431 .
  6. Bombard, Y, Rozmovits, L, Sorvari, A, Daly, C, Carroll, JC, Kennedy, E et al.. Universal tumor screening for Lynch syndrome: health-care providers' perspectives. Genet. Med. 2017;19 (5):568-574. doi: 10.1038/gim.2016.150. PubMed PMID:27711070 .
  7. Bombard, Y, Miller, FA, Barg, CJ, Patton, SJ, Carroll, JC, Chakraborty, P et al.. A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis. Genet. Med. 2017;19 (4):403-411. doi: 10.1038/gim.2016.125. PubMed PMID:27608173 PubMed Central PMC5319861.
  8. Hayeems, RZ, Miller, FA, Barg, CJ, Bombard, Y, Kerr, E, Tam, K et al.. Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis. Pediatrics. 2016;138 (3):. doi: 10.1542/peds.2016-1052. PubMed PMID:27485696 .
  9. Marshall, DA, Deal, K, Bombard, Y, Leighl, N, MacDonald, KV, Trudeau, M et al.. How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment. BMJ Open. 2016;6 (6):e010981. doi: 10.1136/bmjopen-2015-010981. PubMed PMID:27256091 PubMed Central PMC4893875.
  10. Hayeems, RZ, Miller, FA, Barg, CJ, Bombard, Y, Cressman, C, Painter-Main, M et al.. Using Newborn Screening Bloodspots for Research: Public Preferences for Policy Options. Pediatrics. 2016;137 (6):. doi: 10.1542/peds.2015-4143. PubMed PMID:27244855 .
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto
  • Visiting Investigator, Memorial Sloan Kettering Cancer Center, Clinical Genetics Service
  • Chair, American Society of Human Genetics’ Social Issues Committee
  • Co-lead, Societal Values and Patient Engagement Program, the Canadian Centre for Applied Research in Cancer Control
  • Member, Ontario Genetics Advisory Committee
  • Member, Steering Committee of the Canadian Coalition for Genetic Fairness
  • Member, Provincial Council for Maternal and Child Health’s Maternal-Child Screening Committee
  • Chair, European Huntington Disease Network’s Discrimination Working Group (2009-2010)
  • Member, Cancer Quality Council of Ontario’s Personalized Medicine Steering Committee (2010-2011)
  • Member, Cancer Care Ontario’s Patient Experience and Performance Committee (2013-2015)
  • Member, Patient and Citizen Involvement Working Group, Health Technology Assessment International
  • Member, Ethics Working Group, Health Technology Assessment International